# Knowledge Schema Specification

**Проєкт:** OpenOnco
**Документ:** Knowledge Schema Specification
**Версія:** v0.1 (draft)
**Статус:** Draft для обговорення з командою розробки + Clinical Co-Leads
**Попередні документи:** CHARTER.md, CLINICAL_CONTENT_STANDARDS.md

---

> **Pivot 2026-04-27 — Actionability source.** Первинне джерело
> biomarker-actionability мігровано з **OncoKB** на **CIViC**. Підстава:
> OncoKB Terms of Use прямо забороняють використання даних "for patient
> services" та "generation of reports in a hospital or other patient care
> setting" — що є точним визначенням scope OpenOnco (CHARTER §2). Деталі
> аудиту: [`docs/reviews/oncokb-public-civic-coverage-2026-04-27.md`](../docs/reviews/oncokb-public-civic-coverage-2026-04-27.md).
> CIViC (CC0) тепер — primary actionability source; усі engine-модулі
> названо vendor-neutral (`actionability_*`), що залишає можливість
> повернутися до іншого джерела без переписування schema. Поля
> `oncokb_skip_reason` та інші token-словники, що не виносять рішення
> рендеру, збережені незмінними (vocabulary stays).

---

## Мета документа

Цей документ визначає **технічну структуру даних knowledge base** —
які сутності зберігаються, які поля обов'язкові, як сутності
пов'язані між собою, і як правила (rules) представлені у форматі,
що може виконуватися rule engine.

Без цього документа:
- Розробники не знають, які таблиці/колекції будувати
- Clinical Co-Leads не мають формату для подання рекомендацій
- Неможливо написати ні engine, ні валідатор, ні migration скрипт
- Кожна нозологія моделюється ad-hoc, що руйнує консистентність

Цей документ — **контракт між клінічним і технічним шарами**.

---

## 1. Принципи моделювання

### 1.1. Separation of knowledge and code

Правила, показання, протипоказання — в декларативному форматі (YAML),
не hardcoded у коді. Rule engine інтерпретує декларацію.

**Мотивація:** клініцист повинен мати змогу редагувати knowledge base
без участі розробника. Зміна в NCCN guideline → редагування YAML →
pull request → review → merge. Без code changes.

### 1.2. Immutability through versioning

Кожна сутність має версію. Старі версії зберігаються вічно (retention
policy у Charter §10). Update = нова версія, не overwrite.

### 1.3. Traceability

Кожна рекомендація посилається на sources (Tier 1-5 per CCS §2).
Dangling reference = invalid entity.

### 1.4. Explicit unknowns

"Невідомо" — це `unknown` enum value, не `null`. Різниця важлива: null
може означати "не заповнено", unknown означає "явно невідомо для цього
пацієнта". Rule engine трактує їх по-різному.

### 1.5. Standards-based, not bespoke

Використовуємо стандартні vocabularies (SNOMED CT, LOINC, RxNorm,
ICD-O-3) для кодування, не винаходимо свої коди.

### 1.6. No composite scoring

Schema не містить `composite_rating` чи `overall_score`. Evidence
level і strength of recommendation зберігаються окремо (per CCS §4).

---

## 2. Top-level entities (огляд)

Всього 12 основних сутностей:

```
┌──────────────────────────────────────────────────────────────────┐
│                     KNOWLEDGE BASE                                │
├──────────────────────────────────────────────────────────────────┤
│                                                                   │
│  Disease ─────┐                                                   │
│               ├──── Indication ─────── Regimen ─────── Drug       │
│  Biomarker ──┤         │                   │                      │
│               │         │                   └── Contraindication  │
│  Stage  ─────┘         │                                          │
│                         │                                          │
│                         └── Source (evidence refs)                 │
│                                                                    │
│  RedFlag ─────────── (modifies Indication selection)              │
│                                                                    │
│  Test ────────────── (pre-treatment / monitoring)                  │
│                                                                    │
│  SupportiveCare ──── (linked to Regimen or RiskProfile)           │
│                                                                    │
│  MonitoringSchedule ─ (linked to Regimen + Phase)                 │
│                                                                    │
│  Algorithm ────────── (decision tree referencing Indications)     │
│                                                                    │
└──────────────────────────────────────────────────────────────────┘
```

Patient entity — окремий шар (див. документ 3: Data Standards /
mCODE). Тут ми моделюємо лише knowledge, не пацієнтські дані.

---

## 3. Entity: Disease

Нозологія з класифікацією за WHO.

### 3.1. Schema

```yaml
# File: knowledge_base/diseases/hcv_mzl.yaml

entity_type: Disease
id: DIS-HCV-MZL
version: "1.0.0"
created: "2026-04-01"
last_reviewed: "2026-04-15"
reviewers: [reviewer-id-1, reviewer-id-2]

# Classification
names:
  preferred: "HCV-associated marginal zone lymphoma"
  ukrainian: "HCV-асоційована лімфома маргінальної зони"
  synonyms:
    - "HCV-related MZL"
    - "Hepatitis C-associated marginal zone lymphoma"
  abbreviations: ["HCV-MZL"]

codes:
  icd_o_3: "9699/3"
  icd_10: "C85.1"
  snomed_ct: "118605005"
  who_classification:
    edition: "5th"
    year: 2024
    entity: "Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue"
    category: "Mature B-cell neoplasms"

# Clinical characteristics
lineage: "B-cell"
cell_of_origin: "Marginal zone B-cell"
typical_sites:
  - "Spleen"
  - "Extranodal (MALT variants)"
  - "Lymph nodes (NMZL)"

# Etiological drivers (for archetype classification)
etiological_factors:
  - factor: "HCV chronic infection"
    strength: "causal"  # causal | associated | background
    source_refs: [SRC-FERRI-2008, SRC-ARCAINI-2016]

# Epidemiology (optional, for context)
epidemiology:
  incidence_global: "1-2 per 100,000/year (MZL overall)"
  hcv_mzl_proportion: "20-30% of NMZL in HCV-endemic regions"

# Archetype — determines document structure for this disease
archetype: "etiologically_driven"
# Valid values: etiologically_driven | biomarker_driven | stage_driven |
#               risk_stratified | line_of_therapy_sequential

# Linked entities
related_diseases:
  - {id: DIS-MZL-SPLENIC, relation: "variant"}
  - {id: DIS-DLBCL-TRANSFORMATION, relation: "can_transform_to"}

metadata:
  maintainer_domain: "hematologic_malignancies"
  priority_for_mvp: true
  notes: >
    First reference disease for the project. Chosen because it has
    well-defined etiological driver (HCV), clear guidelines (NCCN,
    ESMO, EASL), and reference document exists (HCV-MZL case V.0.0).
```

### 3.2. Required fields

- `entity_type`, `id`, `version`
- `names.preferred`
- `codes.icd_o_3` (обов'язково для всіх онкологічних)
- `codes.who_classification.entity`
- `lineage`
- `archetype`
- `last_reviewed`, `reviewers`

### 3.3. Archetype values

Based on CDSS architecture analysis (see project docs):

| Archetype | Meaning | Example diseases |
|---|---|---|
| `etiologically_driven` | Causal agent removal is part of treatment | HCV-MZL, MALT/H.pylori, HPV-OPC |
| `biomarker_driven` | Molecular profile primarily determines Rx | EGFR+ NSCLC, HER2+ BC, BRAF+ melanoma |
| `stage_driven` | Stage is primary therapy split | Early-stage breast, CRC |
| `risk_stratified` | Prognostic classification dominant | AML, CLL, multiple myeloma |
| `line_of_therapy_sequential` | Treatment = sequential lines | Metastatic NSCLC, mCRC 2L+ |

Archetype determines document template structure.

---

## 4. Entity: Biomarker

Молекулярний, гістологічний, лабораторний маркер.

### 4.1. Schema

```yaml
# File: knowledge_base/biomarkers/ki67.yaml

entity_type: Biomarker
id: BIO-KI67
version: "1.0.0"

names:
  preferred: "Ki-67"
  full_name: "Ki-67 proliferation index"
  alternative: "MIB-1"

codes:
  loinc: "85319-2"
  snomed_ct: "386030001"

# Type
biomarker_type: "protein_expression_ihc"
# Valid: mutation | fusion | amplification | deletion |
#         protein_expression_ihc | protein_expression_flow |
#         msi_status | tmb | methylation | chromosomal |
#         serum_marker | other

# Measurement
measurement:
  method: "immunohistochemistry"
  units: "percent"
  typical_range: [0, 100]
  rounding: "nearest 5%"

# Clinical interpretation cutoffs
# NOTE: cutoffs are disease-specific; stored in Indication entities,
# not here. This field shows general interpretation guidance.
interpretation_notes: >
  Proliferation index. Higher values indicate more rapidly dividing
  tumor. Cutoffs for clinical decisions vary by disease entity
  (e.g., ≥30% in some lymphomas triggers consideration of aggressive
  regimens; ≥20% in breast cancer correlates with luminal B subtype).

# Technical requirements
specimen_requirements:
  specimen_type: ["FFPE tissue", "Fresh frozen tissue"]
  minimum_cellularity: "sufficient tumor cells (>200 cells preferred)"

# Related biomarkers
related_biomarkers: []

last_reviewed: "2026-04-15"
reviewers: [reviewer-id]
```

### 4.2. Example: mutation biomarker

```yaml
entity_type: Biomarker
id: BIO-EGFR-L858R
names:
  preferred: "EGFR L858R"
  full_name: "Epidermal Growth Factor Receptor, exon 21, L858R mutation"
codes:
  hgvs_protein: "NP_005219.2:p.Leu858Arg"
  hgvs_coding: "NM_005228.5:c.2573T>G"
  oncokb_id: "EGFR_L858R"

biomarker_type: "mutation"
mutation_details:
  gene: "EGFR"
  gene_hugo_id: "3236"
  exon: 21
  type: "missense"
  functional_impact: "activating"

measurement:
  method: ["NGS panel", "PCR-based specific assay"]
  sensitivity_requirement: "allele frequency ≥5% typically detectable"

# OncoKB reference
knowledge_base_ref:
  oncokb: "https://oncokb.org/gene/EGFR/L858R"
  civic: "https://civicdb.org/links/variants/33"
  last_synced: "2026-04-15"
```

### 4.3. Actionability-wiring fields (Phase 1 scaffolding)

Три опційні поля додано на Biomarker для безпечного підключення зовнішньої
biomarker-actionability бази (CIViC у v0.1 після pivot 2026-04-27 — див.
callout на початку документа). Поля свідомо vendor-neutral named — engine
переключається з OncoKB на CIViC без зміни schema. Це чисто інженерне
розширення схеми; жодного клінічного контенту в `bio_*.yaml` ця версія
не торкається — заповнення полів виконується у фазі 2.

#### `actionability_lookup` (опційно)

Явний хінт, що дозволяє actionability-екстрактору запитати анотацію саме
для цього біомаркера у зовнішній КБ (CIViC). Якщо поле відсутнє, екстрактор
повністю **пропускає** біомаркер — це навмисно, щоб уникнути мовчазного
«вгадування» (gene, variant) із id, що ризикує дати клініцисту false negative.

Поле раніше називалось `oncokb_lookup` (Phase 1 scaffolding); перейменоване
на `actionability_lookup` у Phase 1.5-міграції (commit `c72e45b`,
2026-04-27) разом з pivot до CIViC. Семантика і прийняті форми не
змінилися.

```yaml
actionability_lookup:
  gene: "BRAF"            # HGNC symbol, uppercase, 1..32 chars
  variant: "V600E"        # короткий HGVS-p / структурний дескриптор / fs
```

Прийнятні форми `variant`:
- короткий HGVS-p: `V600E`, `L858R`, `G12C`
- структурні: `Exon 19 deletion`, `E746_A750del`
- frameshift-токени: `W288fs`
- fusion-нотація CIViC: `BCR::ABL1` (пара генів через `::`), у т.ч.
  з вкладеними резистентними мутаціями у `variant` (`Fusion AND ABL1 T315I`)

Повна валідація HGVS живе в `engine/civic_variant_matcher.py` (попередньо
`engine/oncokb_extract.py:normalize_variant`). Схема робить тільки type-check.

#### `oncokb_skip_reason` (опційно)

Стабільний machine-readable токен, що пояснює, чому біомаркер навмисно
**виключений** з actionability-запитів. Ім'я поля збережено історично
(token-словник source-agnostic — ті самі причини виключення діють і для
CIViC, і для OncoKB). Ці рядки греп-стійкі — downstream код
(`engine/_actionability.py`) ключує поведінку саме на них, тож
перейменування без координації заборонене.

Допустимі значення (`Literal`):

| Token | Коли |
|---|---|
| `ihc_no_variant` | IHC без молекулярного варіанту (Ki-67, CD20, …) |
| `score` | Скор/індекс (IPI, MIPI, GIPSS) |
| `clinical_composite` | Композитний клінічний маркер |
| `serological` | Серологія (HCV-Ab, HBsAg) |
| `viral_load` | Вірусне навантаження (HCV-RNA, HBV-DNA) |
| `tumor_marker` | Загальний пухлинний маркер (CA-125, AFP, β-hCG) |
| `imaging` | Imaging-патерн |
| `germline_no_somatic` | Лише герм-лайн варіант, без соматичної актнабельності |
| `fusion_mvp` | Fusion — поза скоупом MVP |
| `itd_mvp` | ITD-варіанти (FLT3-ITD) — поза скоупом MVP |
| `multi_allele_mvp` | Мультиалельні випадки — поза скоупом MVP |
| `tumor_agnostic` | Tumor-agnostic indication — окремий шлях |

Взаємно виключає `actionability_lookup`. Допустимі стани: «жоден не заданий»
(біомаркер ще не триаговано), «лише lookup», «лише skip_reason». Обидва
одночасно → ValidationError.

#### `external_ids` (опційно)

Крос-референси на зовнішні KB. Усі ключі опційні; часткове заповнення
(наприклад, лише `hgnc_symbol`) — нормально.

```yaml
external_ids:
  hgnc_symbol: "EGFR"
  hgnc_id: "HGNC:3236"
  oncokb_url: "https://oncokb.org/gene/EGFR/L858R"
  civic_id: "33"
  civic_url: "https://civicdb.org/links/variants/33"
  clingen_id: "CA123456"
  hgvs_protein: "NP_005219.2:p.Leu858Arg"
  hgvs_coding: "NM_005228.5:c.2573T>G"
```

Поле незалежне від `actionability_lookup` / `oncokb_skip_reason` — може
бути заповнене у будь-якій комбінації. `oncokb_url` залишено в словнику
як read-only legacy-метадані: рендер їх не використовує (див. §4.4 щодо
ToS-обмежень OncoKB), але цитати з опублікованих наукових праць можуть
посилатися на стабільну OncoKB-сторінку без redistribution-конфлікту.

---

### 4.4. Entity: BiomarkerActionability (BMA)

Окрема сутність, яка маппить пару (gene-variant, tumor type) на
клінічну actionability-tier за ESCAT (ESMO Scale for Clinical Actionability
of molecular Targets, Mateo 2018). Композує існуючі `BIO-*` (gene/variant
taxonomy) та `DIS-*` (disease taxonomy) у per-tumor клінічну
інтерпретацію. Pydantic-схема: `knowledge_base/schemas/biomarker_actionability.py`.

**ID convention:** `BMA-{biomarker}-{variant?}-{disease}`, наприклад
`BMA-BRAF-V600E-CRC`, `BMA-EGFR-T790M-NSCLC`. `biomarker_id` може вже
кодувати variant (e.g. `BIO-BRAF-V600E`); тоді `variant_qualifier` —
опційний рефайнмент (sub-variant / co-occurrence). `null` у
`variant_qualifier` → клітинка gene-level (будь-яка патогенна
альтерація трактується ідентично).

#### 4.4.1. Канонічна схема (post-pivot)

```yaml
# File: knowledge_base/hosted/content/biomarker_actionability/bma_braf_v600e_crc.yaml

entity_type: BiomarkerActionability
id: BMA-BRAF-V600E-CRC
biomarker_id: BIO-BRAF-V600E         # FK → BIO-*
variant_qualifier: null               # null → весь варіант, що в biomarker_id
disease_id: DIS-CRC                  # FK → DIS-*

# ── Primary actionability tier (vendor-neutral) ────────────────────────
escat_tier: "IA"                     # ESCAT IA|IB|IIA|IIB|IIIA|IIIB|IV|X

# ── Evidence sources block (canonical post-pivot) ──────────────────────
# Замінює legacy-поля oncokb_level / oncokb_snapshot_version. Список
# EvidenceSourceRef-структур; жодне джерело не привілейоване в render.
evidence_sources:
  - source: "SRC-CIVIC"              # FK → Source entity
    level: "B"                       # CIViC level: A|B|C|D|E
    evidence_ids: ["civic:EID-1409", "civic:EID-7821"]
    direction: "supports"            # supports | does_not_support | n/a
    significance: "sensitivity_response"  # sensitivity_response|resistance|reduced_sensitivity|...
    note: "Encorafenib + cetuximab in BRAF V600E mCRC after prior therapy."
  - source: "SRC-NCCN-COLORECTAL-2025"
    level: "category_1"              # NCCN-specific level vocabulary
    evidence_ids: []
    direction: "supports"
    significance: "sensitivity_response"
    note: "Preferred 2L+ regimen for V600E."

# ── Two-reviewer gate flag (CHARTER §6.1) ─────────────────────────────
# True → блокує publish до двох клінічних sign-off. Виставляється
# loader'ом якщо drafted_by починається з "claude_extraction" або якщо
# evidence_sources містить лише A/B без guideline-corroboration.
actionability_review_required: true

# ── Per-jurisdiction regulatory ─────────────────────────────────────
regulatory_approval:
  fda: ["encorafenib + cetuximab — BRAF V600E mCRC (FDA 2020)"]
  ema: ["encorafenib + cetuximab — BRAF V600E mCRC (EMA 2020)"]
  ukraine: []

recommended_combinations:
  - "encorafenib + cetuximab (2L+ V600E mCRC per SRC-NCCN-COLORECTAL-2025)"
contraindicated_monotherapy:
  - "BRAF inhibitor monotherapy (paradoxical MAPK activation)"

primary_sources:                      # ≥1 required (loader-enforced)
  - SRC-NCCN-COLORECTAL-2025
  - SRC-CIVIC
last_verified: "2026-04-27"
reviewer_signoffs: []                 # ≥2 to publish per CHARTER §6.1
notes: >
  ESCAT IA. Resistance: MAPK reactivation through MEK or PI3K — see
  triplet trials.
```

#### 4.4.2. `EvidenceSourceRef` shape

```
EvidenceSourceRef = {
  source:        str,        # FK → SRC-*  (required)
  level:         str,        # source-specific level token (required)
  evidence_ids:  list[str],  # source-native IDs, e.g. "civic:EID-1409"
  direction:     "supports" | "does_not_support" | "n/a",
  significance:  str,        # "sensitivity_response" | "resistance" |
                             # "reduced_sensitivity" | "predisposition" |
                             # "better_outcome" | "poor_outcome" | ...
  note:          Optional[str],
}
```

`level` — це **source-native токен** (CIViC `A|B|C|D|E`, NCCN
`category_1|2A|2B|3`, ESMO `I|II|III|IV|V`). Vendor-mapping (наприклад,
CIViC-A → ESCAT IA) лежить у render-шарі, не в YAML — клінічна
відповідальність за сumulative-tier (`escat_tier`) залишається на
рев'юері BMA, не на автоматичному маппінгу.

Поле `direction == "does_not_support"` є load-bearing: render має
показати такий запис як **anti-evidence card** (negative recommendation),
а не приховати. CIViC містить ~10% таких записів — це навмисний клінічний
сигнал, який engine не повинен мовчазно дропати.

#### 4.4.3. `escat_tier` як primary actionability tier

`escat_tier` — vendor-neutral, опубліковано-стабільний (Mateo 2018 не
оновлюється щодня, на відміну від OncoKB level scheme). Це поле — те,
що render використовує як основний тіер у Plan-картках. Окремі
`evidence_sources[*].level` — це доказова база для sign-off, не
користувацький рендер-токен.

#### 4.4.4. Legacy-поля та ToS-обмеження

Поля `oncokb_level` і `oncokb_snapshot_version`, що існували у Phase 0
draft-yaml-ах, **видалено зі схеми** в Phase 1.5-міграції (engine commit
`5384348`, schema-міграція YAML — pending Part B). Якщо запис у
`evidence_sources` має `source: "SRC-ONCOKB"`, він трактується render-шаром
як **legacy metadata**: не виводиться у користувацький UI, не використовується
як основа для рекомендації. Підстава — OncoKB Terms of Use (Phase-4 правило
рендеру; деталі див. `SOURCE_INGESTION_SPEC.md` §2.5 і
`docs/reviews/oncokb-public-civic-coverage-2026-04-27.md` §3.3).

#### 4.4.5. Статус формалізації

Сутність додано до Pydantic-схеми (`knowledge_base/schemas/biomarker_actionability.py`)
2026-04-26 під CSD Lab pitch і не потрапила в §2 top-level entities у
v0.1-draft цього документа. Цей розділ — закрепачення BMA як
повноправної сутності 13-го рівня для майбутнього перегляду §2 і
data-model-діаграми (§15).

---

## 5. Entity: Drug

Окремий препарат.

### 5.1. Schema

```yaml
# File: knowledge_base/drugs/rituximab.yaml

entity_type: Drug
id: DRUG-RITUXIMAB
version: "1.0.0"

names:
  generic: "rituximab"
  ukrainian: "ритуксимаб"
  brand_names: ["Rituxan", "MabThera", "Truxima (biosimilar)", "Ruxience (biosimilar)"]
  atc_code: "L01FA01"
  inn: "rituximab"

codes:
  rxnorm: "121191"
  snomed_ct: "386919002"
  ndc: []  # multiple; per-formulation basis

# Drug class
drug_class:
  primary: "monoclonal_antibody"
  mechanism: "anti-CD20 monoclonal antibody"
  target: "CD20 (B-cell surface marker)"

# Regulatory status
regulatory_status:
  fda:
    approved: true
    first_approval_year: 1997
    indications_link: ["NCCN-B-Cell-Lymphomas", "multiple"]
  ema:
    approved: true
  ukraine_registration:
    registered: true
    registration_number: "[filled by UA regulatory lookup]"
    reimbursed_nszu: true
    reimbursement_indications: ["specific - see НСЗУ list"]

# Dosing (generic; disease-specific doses in Regimen entity)
typical_dosing:
  standard_dose: "375 mg/m²"
  standard_route: "intravenous infusion"
  notes: >
    Dose varies by disease and line of therapy. See Regimen entities
    for disease-specific dosing. Infusion rate protocols apply.

# Formulations available
formulations:
  - {form: "solution_for_infusion", strength: "10 mg/mL", volumes: ["10 mL", "50 mL"]}
  - {form: "subcutaneous_injection", strength: "120 mg/mL", note: "1400 mg fixed dose"}

# Contraindications (general; disease-specific in Contraindication entity)
absolute_contraindications:
  - "Known severe hypersensitivity to rituximab or murine proteins"
  - "Active severe infection"

# Safety warnings
black_box_warnings:
  - warning: "Fatal infusion reactions"
    source: "FDA label, updated 2024"
  - warning: "Severe mucocutaneous reactions"
    source: "FDA label"
  - warning: "Hepatitis B reactivation"
    source: "FDA label"
  - warning: "Progressive multifocal leukoencephalopathy (PML)"
    source: "FDA label"

# Important drug interactions
interactions:
  - with: "live vaccines"
    severity: "contraindicated"
    mechanism: "immune suppression reduces immune response"

# Key toxicities
common_adverse_events:
  - {event: "infusion_reaction", frequency: "10-20%", grade: "typically 1-2"}
  - {event: "neutropenia", frequency: "15-30%", grade: "3-4: 5-10%"}
  - {event: "infection", frequency: "variable"}
  - {event: "tumor_lysis_syndrome", frequency: "rare; depends on disease burden"}

# Pharmacology
pharmacology:
  half_life_days: [11, 30]  # range
  elimination: "Reticuloendothelial system; not renal"
  crosses_bbb: false

source_refs: [SRC-RITUXIMAB-FDA-LABEL, SRC-NCCN-BCELL-V2-2026]

last_reviewed: "2026-04-15"
reviewers: [reviewer-id-1, reviewer-id-2]
```

### 5.2. Required fields

- `id`, `names.generic`, `names.ukrainian`
- `drug_class.mechanism`
- `regulatory_status.ukraine_registration.registered`
- `absolute_contraindications`
- At least one `source_refs`

---

## 6. Entity: Regimen

Лікувальна схема — комбінація препаратів з графіком.

### 6.1. Schema

```yaml
# File: knowledge_base/regimens/br.yaml

entity_type: Regimen
id: REG-BR-LYMPHOMA
version: "1.0.0"

names:
  preferred: "Bendamustine-Rituximab (BR)"
  acronym: "BR"
  ukrainian: "Бендамустин + Ритуксимаб (BR)"

# Components
components:
  - drug_id: DRUG-BENDAMUSTINE
    dose: "90 mg/m²"
    route: "intravenous"
    schedule: "days 1-2 of each cycle"
    order: 1
  - drug_id: DRUG-RITUXIMAB
    dose: "375 mg/m²"
    route: "intravenous"
    schedule: "day 1 of each cycle"
    order: 2
    notes: "May be given as day 0 per institutional protocol"

# Cycle structure
cycle_length_days: 28
total_cycles: 6
total_duration_weeks: 24

# Intent
typical_intent: ["curative", "palliative"]
# Specific intent determined per Indication

# Dose modifications
dose_adjustments:
  - condition: "FIB-4 > 3.25 OR cirrhosis"
    modification: "Reduce bendamustine to 70 mg/m²"
    rationale: "Hepatic dysfunction increases bendamustine toxicity"
    source_refs: [SRC-EMA-BENDAMUSTINE-SmPC]
  - condition: "ECOG >= 2 OR age >= 75"
    modification: "Consider bendamustine 70-80 mg/m²"
    rationale: "Reduced tolerance in frail patients"
  - condition: "CrCl < 30 mL/min"
    modification: "Not recommended; use alternative regimen"

# Toxicity profile (summary)
toxicity_profile:
  myelosuppression: "moderate-severe"
  cardiotoxicity: "low"
  neurotoxicity: "low"
  hepatotoxicity: "moderate"
  nephrotoxicity: "low"
  alopecia: "moderate"
  emetogenic_risk: "moderate"
  treatment_related_mortality_percent: [1, 2]

# Required premedication
premedication:
  rituximab:
    - "paracetamol 1000 mg PO"
    - "diphenhydramine 25-50 mg PO or IV"
    - "methylprednisolone 100 mg IV (or equivalent)"
  bendamustine:
    - "ondansetron 8 mg IV or equivalent 5-HT3 antagonist"
    - "dexamethasone 8-12 mg IV"

# Required supportive care
mandatory_supportive_care:
  - id: SUPP-PJP-PROPHYLAXIS
    notes: "Cotrimoxazole 480 mg daily during treatment + 6 months"
  - id: SUPP-ANTIVIRAL-PROPHYLAXIS
    notes: "Acyclovir 400 mg BID during treatment + 6 months"
  - id: SUPP-HBV-SCREENING-PROPHYLAXIS
    notes: "Required per CCS §3 — see Contraindication CONTRA-HBV"

# Monitoring during regimen
monitoring_schedule_id: MON-BR-STANDARD

# Ukraine availability
ukraine_availability:
  bendamustine:
    registered: true
    reimbursed_nszu: true  # verify current
    typical_cost_per_cycle_uah: "[to fill from pricing analysis]"
  rituximab:
    registered: true
    reimbursed_nszu: true
    biosimilar_available: true

source_refs:
  - SRC-NCCN-BCELL-V2-2026
  - SRC-ESMO-MZL-2020
  - SRC-BRIGHT-TRIAL-FLINN-2019
  - SRC-STIL-NHL1-RUMMEL-2013

last_reviewed: "2026-04-15"
reviewers: [reviewer-id-hem-1, reviewer-id-hem-2]
```

### 6.2. Required fields

- `id`, `names.preferred`, `names.ukrainian`
- `components` (список з мінімум одного Drug)
- `cycle_length_days`
- `total_cycles` OR `total_duration_weeks`
- `toxicity_profile`
- `monitoring_schedule_id`
- At least one `source_refs`

### 6.3. Toxicity profile values

For each toxicity category, use enum:
- `none`
- `low`
- `moderate`
- `severe`
- `variable` (з описом в `notes`)

Numeric rates (where available) в окремих полях з джерелом.

---

## 7. Entity: Indication

**Найважливіша сутність.** Пов'язує Disease + clinical profile → Regimen
з рівнем доказовості.

### 7.1. Schema

```yaml
# File: knowledge_base/indications/hcv_mzl_1l_standard.yaml

entity_type: Indication
id: IND-HCV-MZL-1L-STANDARD
version: "1.0.0"

# What clinical scenario this covers
applicable_to:
  disease_id: DIS-HCV-MZL
  line_of_therapy: 1  # 1 = first-line; 2 = second-line; etc.
  stage_requirements:
    stages: ["all"]  # or specific: ["I-II", "III-IV"]
  biomarker_requirements:
    required:
      - biomarker_id: BIO-HCV-RNA-POSITIVE
        value_constraint: "positive"
    excluded:
      - biomarker_id: BIO-TRANSFORMATION-MARKERS
        value_constraint: "negative"
  demographic_constraints:
    age_range: [18, null]  # null = no upper limit
    performance_status_max: 2  # ECOG
  additional_constraints:
    - "No red flags for histological transformation"

# The recommendation
recommended_regimen_id: REG-BR-LYMPHOMA
concurrent_therapy:
  - regimen_id: REG-DAA-SOFOSBUVIR-VELPATASVIR
    timing: "concurrent_with_br"
    rationale: "HCV eradication removes antigenic driver; safe co-administration confirmed"

# Sequential/maintenance phase
followed_by:
  - regimen_id: REG-RITUXIMAB-MAINTENANCE
    timing: "after_completion_of_induction"
    duration: "2 years (q8w × 12 doses)"
    rationale: "BRIGHT trial: EFS 81% → 94% with maintenance"

# Evidence assessment (per CCS §4)
evidence_level: "moderate"
# high | moderate | low | very_low
evidence_level_rationale: >
  Phase 2 BArT trial (Arcaini 2014, N=44); supported by retrospective
  analyses and aligned with NCCN/ESMO recommendations. No Phase 3 RCT
  specifically for HCV-MZL 1L (HCV-MZL too rare for dedicated Phase 3).

strength_of_recommendation: "preferred"
# preferred | alternative | not_recommended | insufficient_evidence
strength_rationale: >
  Consensus across NCCN, ESMO, and EASL recommendations. Benefit-harm
  balance clearly favorable in appropriate population. Lower toxicity
  than historical R-CHOP with equivalent efficacy in non-transformed MZL.

nccn_category: "2A"  # 1 | 2A | 2B | 3 | N/A

# Expected outcomes (key evidence numbers)
expected_outcomes:
  overall_response_rate:
    value: "85-90%"
    source_ref: SRC-BRIGHT-TRIAL
    notes: "For BR in indolent lymphomas broadly"
  complete_response:
    value: "~60%"
    source_ref: SRC-BRIGHT-TRIAL
  progression_free_survival:
    median_months: 42
    source_ref: SRC-BRIGHT-TRIAL
    note: "For indolent NHL; HCV-MZL-specific data limited"
  hcv_cure_rate_svr12:
    value: "95-98%"
    source_ref: SRC-EASL-HCV-2023
  overall_survival_5y:
    value: "80-85%"
    source_ref: SRC-ARCAINI-2016

# Contraindications (hard)
hard_contraindications: [CONTRA-AMIODARONE-SOFOSBUVIR, CONTRA-HBV-NO-PROPHYLAXIS]

# Red flags that should trigger alternative indication
red_flags_triggering_alternative:
  - red_flag_id: RF-B-SYMPTOMS
    alternative_indication: IND-HCV-MZL-1L-AGGRESSIVE
  - red_flag_id: RF-LDH-HIGH
    alternative_indication: IND-HCV-MZL-1L-AGGRESSIVE
  - red_flag_id: RF-BULKY-DISEASE
    alternative_indication: IND-HCV-MZL-1L-AGGRESSIVE
  - red_flag_id: RF-RAPID-PROGRESSION
    alternative_indication: IND-HCV-MZL-1L-AGGRESSIVE

# Pre-treatment workup
required_tests: [TEST-CBC, TEST-LFT-COMPREHENSIVE, TEST-HCV-RNA-QUANT, TEST-HBV-SEROLOGY, TEST-FIB-4]
desired_tests: [TEST-ECHO-LVEF, TEST-LDH, TEST-B2-MICROGLOBULIN]

# Sources
sources:
  - id: SRC-NCCN-BCELL-V2-2026
    section: "MZL-3, MZL-4"
    weight: "primary"
  - id: SRC-ESMO-MZL-2020
    weight: "primary"
  - id: SRC-EASL-HCV-2023
    weight: "primary_for_daa_component"
  - id: SRC-BART-ARCAINI-2014
    weight: "supporting_phase2"
  - id: SRC-BRIGHT-FLINN-2019
    weight: "supporting_phase3_indolent_broad"

# Controversies (per CCS §1.2 — show, don't hide)
known_controversies:
  - topic: "Bendamustine dosing in elderly/cirrhotic"
    positions:
      - "NCCN: 90 mg/m² standard"
      - "ESMO: consider 70 mg/m² for elderly/cirrhotic"
    resolution: "Implemented as dose_adjustment in Regimen"

last_reviewed: "2026-04-15"
reviewers: [reviewer-id-hem-1, reviewer-id-hem-2]
```

### 7.2. Required fields

- `id`, `version`
- `applicable_to.disease_id`, `applicable_to.line_of_therapy`
- `recommended_regimen_id`
- `evidence_level`, `strength_of_recommendation`
- `hard_contraindications` (may be empty array)
- Minimum 2 `sources` of Tier 1 or Tier 2 (per CCS §6.1)

### 7.3. The two-plan architecture

For the project's core use case (generating two alternative plans),
pairs of Indications are created:

```
IND-HCV-MZL-1L-STANDARD   (less intensive)
IND-HCV-MZL-1L-AGGRESSIVE (more intensive)
```

Linked by shared `applicable_to` but different `recommended_regimen_id`
and `red_flags_triggering_alternative` bidirectionally.

Algorithm entity (§12) determines which is "default" vs "alternative"
for a given patient.

---

## 8. Entity: Contraindication

Hard rules that prevent regimen use.

### 8.1. Schema

```yaml
# File: knowledge_base/contraindications/amiodarone_sofosbuvir.yaml

entity_type: Contraindication
id: CONTRA-AMIODARONE-SOFOSBUVIR
version: "1.0.0"

# Severity
severity: "absolute"
# absolute | relative | caution

# Trigger condition (machine-readable)
trigger:
  type: "drug_drug_interaction"
  conditions:
    - patient_current_medication_includes: DRUG-AMIODARONE
    - proposed_regimen_contains: DRUG-SOFOSBUVIR
  logic: "AND"  # all conditions must be true

# Human-readable description
description:
  english: >
    Concurrent use of sofosbuvir and amiodarone can cause severe,
    potentially fatal bradyarrhythmia. This combination is absolutely
    contraindicated.
  ukrainian: >
    Одночасне використання софосбувіру та аміодарону може спричинити
    важку, потенційно фатальну брадиаритмію. Ця комбінація абсолютно
    протипоказана.

# What to do instead
alternative_actions:
  - "Use DAA combination that does not include sofosbuvir (e.g., glecaprevir/pibrentasvir)"
  - "If sofosbuvir essential, discontinue amiodarone ≥6 months before (long half-life)"
  - "Consult cardiology for amiodarone alternatives"

# Sources
sources:
  - id: SRC-FDA-SOFOSBUVIR-LABEL
    section: "Boxed Warning"
  - id: SRC-BACK-2015-DRUG-INTERACTION

# Related entities
affects_indications:
  - IND-HCV-MZL-1L-STANDARD
  - IND-HCV-MZL-1L-AGGRESSIVE
  - IND-HCV-ANY-WITH-SOFOSBUVIR  # generic

last_reviewed: "2026-04-15"
reviewers: [reviewer-id-pharm, reviewer-id-hem]
```

### 8.2. Severity levels

| Severity | Meaning | Engine behavior |
|---|---|---|
| `absolute` | Never proceed with this combination | Regimen excluded; show hard block |
| `relative` | Proceed only with specific precautions | Show warning; require acknowledgment |
| `caution` | Proceed with monitoring | Show informational note |

### 8.3. Trigger types

- `patient_condition` — patient has specific diagnosis/status
- `lab_value` — lab value outside range
- `medication` — patient on specific drug
- `drug_drug_interaction` — proposed + existing drug conflict
- `allergy` — documented allergy
- `prior_treatment` — specific prior treatment history
- `biomarker_status` — specific biomarker value/absence
- `demographic` — age/sex-specific

---

## 9. Entity: RedFlag

Clinical findings that shift treatment intensity choice.

### 9.1. Schema

```yaml
# File: knowledge_base/red_flags/b_symptoms.yaml

entity_type: RedFlag
id: RF-B-SYMPTOMS
version: "1.0.0"

names:
  preferred: "B symptoms"
  ukrainian: "B-симптоми"

# What defines it
definition:
  english: >
    Constitutional symptoms of lymphoma including: unexplained fever >38°C,
    drenching night sweats, or unexplained weight loss >10% body weight
    over 6 months.
  ukrainian: >
    Загальні симптоми лімфоми: незрозуміла лихоманка >38°C, нічна
    пітливість, втрата ваги >10% за 6 місяців.

# Trigger (machine-readable)
trigger:
  type: "symptom_composite"
  any_of:
    - {symptom: "fever_unexplained", threshold_celsius: 38.0, duration: ">2 weeks"}
    - {symptom: "night_sweats_drenching"}
    - {symptom: "weight_loss_unexplained", threshold_percent: 10, duration_months: 6}

# Clinical implication
clinical_direction: "intensify"
# intensify | de_escalate | hold | investigate

# Which diseases this is relevant to
relevant_diseases: [DIS-HCV-MZL, DIS-DLBCL, DIS-FOLLICULAR-LYMPHOMA, DIS-HODGKIN]

# In MVP: linked to alternative indication logic
shifts_algorithm:
  from_indication: IND-HCV-MZL-1L-STANDARD
  to_indication: IND-HCV-MZL-1L-AGGRESSIVE
  strength: "strong_indication_to_shift"
  # strong_indication_to_shift | consider_shift | weak_signal

source_refs: [SRC-LUGANO-CLASSIFICATION, SRC-NCCN-BCELL-V2-2026]
last_reviewed: "2026-04-15"
reviewers: [reviewer-id]
```

---

## 10. Entity: Test

Clinical tests — pre-treatment workup and monitoring.

### 10.1. Schema

```yaml
# File: knowledge_base/tests/hcv_rna_quant.yaml

entity_type: Test
id: TEST-HCV-RNA-QUANT
version: "1.0.0"

names:
  preferred: "HCV RNA quantitative PCR"
  ukrainian: "HCV-RNA ПЛР кількісний"

codes:
  loinc: "11011-4"

category: "virology"
# hematology | biochemistry | virology | immunology | imaging |
# pathology | molecular | cardiac | other

purpose:
  - "Baseline HCV viral load before DAA treatment"
  - "Monitoring response to DAA"
  - "Detection of SVR12 (sustained virologic response)"

specimen:
  type: "blood"
  volume_ml: 5
  tube: "EDTA or SST"

turnaround_time_business_days: [2, 5]

priority_class: "critical"
# critical | standard | desired | calculation_based

availability_ukraine:
  state_funded: true
  typical_cost_uah: "[estimate; varies]"
  typical_availability: "widely available in oncology centers"

linked_to_regimens: [REG-DAA-SOFOSBUVIR-VELPATASVIR]
linked_to_diseases: [DIS-HCV-MZL, DIS-HCV-DLBCL, DIS-HCV-ANY]

source_refs: [SRC-EASL-HCV-2023]
last_reviewed: "2026-04-15"
reviewers: [reviewer-id]
```

### 10.2. Priority classes

Follows HCV-MZL reference document convention:
- `critical` — must have before treatment decision
- `standard` — routine part of workup
- `desired` — helpful but not blocking
- `calculation_based` — derived from other tests (e.g., FIB-4, BSA)

---

## 11. Entity: SupportiveCare

Profylactic and supportive interventions.

### 11.1. Schema

```yaml
# File: knowledge_base/supportive_care/pjp_prophylaxis.yaml

entity_type: SupportiveCare
id: SUPP-PJP-PROPHYLAXIS
version: "1.0.0"

names:
  preferred: "PJP (Pneumocystis jirovecii) prophylaxis"
  ukrainian: "Профілактика пневмоцистної пневмонії"

intervention_type: "pharmacological"
# pharmacological | procedural | nutritional | psychosocial | monitoring

# What
standard_intervention:
  drug_id: DRUG-COTRIMOXAZOLE
  dose: "480 mg once daily OR 960 mg three times weekly"
  route: "oral"
  duration: "during_immunosuppressive_therapy + 6 months post"

alternatives:
  - {drug_id: DRUG-DAPSONE, condition: "sulfa allergy", dose: "100 mg daily"}
  - {drug_id: DRUG-ATOVAQUONE, condition: "sulfa allergy, dapsone intolerance"}
  - {drug_id: DRUG-PENTAMIDINE-INHALED, condition: "drug intolerance"}

# When indicated
triggers:
  - {regimen_contains_drug_class: "purine_analog"}
  - {regimen_id: REG-BR-LYMPHOMA}
  - {regimen_id: REG-R-CHOP}
  - {prolonged_corticosteroid_use_days: ">21"}
  - {patient_immunodeficiency: true}

# Rationale
rationale: >
  Regimens causing CD4 lymphopenia (including bendamustine-containing
  and R-CHOP) increase risk of PJP. Prophylaxis reduces incidence from
  ~5% to <1%.

source_refs: [SRC-IDSA-PJP-GUIDELINES, SRC-NCCN-SUPPORTIVE]
last_reviewed: "2026-04-15"
reviewers: [reviewer-id-id, reviewer-id-hem]
```

---

## 12. Entity: MonitoringSchedule

Schedule of tests/visits during regimen.

### 12.1. Schema

```yaml
# File: knowledge_base/monitoring/br_standard.yaml

entity_type: MonitoringSchedule
id: MON-BR-STANDARD
version: "1.0.0"

linked_to_regimen: REG-BR-LYMPHOMA

phases:
  - phase_name: "Pre-treatment"
    window: "week -2 to week 0"
    required_tests: [TEST-CBC, TEST-LFT, TEST-HCV-RNA, TEST-HBV-SEROLOGY, TEST-FIB-4, TEST-ECG]
    desired_tests: [TEST-ECHO-LVEF]
    visits: 1

  - phase_name: "Cycle 1 intensive monitoring"
    window: "weeks 0-4"
    recurring_tests:
      - {test: TEST-CBC, frequency: "weekly"}
      - {test: TEST-CMP, frequency: "weekly"}
    checkpoints:
      - {week: 4, test: TEST-HCV-RNA-QUANT}
    visits: "weekly"

  - phase_name: "Cycles 2-6"
    window: "weeks 4-24"
    recurring_tests:
      - {test: TEST-CBC, frequency: "before each cycle + day 14"}
      - {test: TEST-CMP, frequency: "before each cycle"}
    checkpoints:
      - {week: 12, test: TEST-HCV-RNA-QUANT, note: "Post-DAA completion"}
      - {after_cycle: 3, test: IMAGING-CT-OR-PET, note: "Interim response assessment"}
      - {after_cycle: 6, test: IMAGING-CT-OR-PET, note: "End-of-induction response"}

  - phase_name: "Maintenance (rituximab q8w)"
    window: "weeks 24-128"
    recurring_tests:
      - {test: TEST-CBC, frequency: "before each dose"}
      - {test: TEST-CMP, frequency: "before each dose"}
    checkpoints:
      - {week: 48, test: TEST-HCV-RNA-QUANT, note: "SVR24 confirmation"}
      - {frequency_months: 6, tests: [TEST-LIVER-US, TEST-AFP], note: "HCC screening post-HCV"}

  - phase_name: "Lifelong surveillance"
    window: "after week 128"
    recurring_tests:
      - {frequency_months: [3, 6], test: "clinical_exam"}
      - {frequency_months: [6, 12], test: IMAGING-CT, duration_years: 5}
      - {frequency_months: 6, tests: [TEST-LIVER-US, TEST-AFP], duration: "lifelong"}

source_refs: [SRC-NCCN-BCELL-V2-2026, SRC-EASL-HCV-2023]
last_reviewed: "2026-04-15"
reviewers: [reviewer-id]
```

---

## 13. Entity: Algorithm

Decision tree for two-plan generation.

### 13.1. Schema

```yaml
# File: knowledge_base/algorithms/hcv_mzl_1l_choice.yaml

entity_type: Algorithm
id: ALGO-HCV-MZL-1L-CHOICE
version: "1.0.0"

applicable_to:
  disease_id: DIS-HCV-MZL
  line_of_therapy: 1

# Output
purpose: "Select between standard and aggressive 1L regimen"
output_indications: [IND-HCV-MZL-1L-STANDARD, IND-HCV-MZL-1L-AGGRESSIVE]
default_indication: IND-HCV-MZL-1L-STANDARD

# Decision tree
decision_tree:
  - step: 1
    description: "Are there red flags AGAINST aggressive regimen?"
    evaluate:
      any_of:
        - red_flag: RF-LVEF-LOW
        - red_flag: RF-CIRRHOSIS-OR-FIB4-HIGH
        - red_flag: RF-ECOG-HIGH
        - red_flag: RF-SEVERE-NEUROPATHY
        - red_flag: RF-AMIODARONE
        - red_flag: RF-NO-ECHO-AVAILABLE
        - red_flag: RF-AGE-OVER-75
    if_true:
      result: IND-HCV-MZL-1L-STANDARD
      reason: "Contraindications to aggressive regimen"
      stop: true
    if_false:
      continue_to: 2

  - step: 2
    description: "Are there red flags FOR aggressive regimen?"
    evaluate:
      any_of:
        - red_flag: RF-B-SYMPTOMS
        - red_flag: RF-LDH-HIGH
        - red_flag: RF-RAPID-PROGRESSION
        - red_flag: RF-BULKY-DISEASE
        - red_flag: RF-HYPERCALCEMIA
        - red_flag: RF-HISTOLOGICAL-TRANSFORMATION
    if_true:
      result: IND-HCV-MZL-1L-AGGRESSIVE
      reason: "Indicators for aggressive regimen present"
    if_false:
      result: IND-HCV-MZL-1L-STANDARD
      reason: "Default recommendation (consensus)"

# Output format
always_show_both:
  description: >
    Both standard and aggressive indications are always presented to
    the clinician. Algorithm determines which is marked "default" vs
    "alternative", but both documents are generated for comparison.
  enforcement: "mandatory_two_plan_output"

source_refs: [SRC-NCCN-BCELL-V2-2026, SRC-ESMO-MZL-2020, SRC-ALDERUCCIO-2024]
last_reviewed: "2026-04-15"
reviewers: [reviewer-id-hem-1, reviewer-id-hem-2]
```

---

## 14. Entity: Source

Metadata для будь-якого джерела.

### 14.1. Schema

```yaml
# File: knowledge_base/sources/nccn_bcell_v2_2026.yaml

entity_type: Source
id: SRC-NCCN-BCELL-V2-2026
version: "1.0.0"

source_type: "guideline"
# guideline | phase3_rct | phase2_trial | phase1_trial |
# meta_analysis | systematic_review | regulatory |
# clinical_trial_registry | molecular_kb | monograph | review

title: "NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas"
version_or_edition: "Version 2.2026"
publisher: "National Comprehensive Cancer Network"
publication_year: 2026
publication_date: "2026-02-15"

# For articles
authors: []
journal: null
doi: null
pmid: null

# Access
url: "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480"
access_level: "subscription_required"
# open_access | subscription_required | registered_free | limited

currency_status: "current"
# current | superseded | historical
superseded_by: null
current_as_of: "2026-04-15"

# Tier assignment per CCS §2
evidence_tier: 1

# Licensing & hosting (per SOURCE_INGESTION_SPEC §3)
hosting_mode: "referenced"          # hosted | referenced | mixed
hosting_justification: null         # H1..H5 per SOURCE_INGESTION_SPEC §1.4 (null якщо referenced)
ingestion:
  method: "live_api"                # live_api | scheduled_batch | manual | none
  client: null                      # modulename якщо live_api, null інакше
  endpoint: null
  rate_limit: null
cache_policy:
  enabled: false
  ttl_hours: null
  scope: null                       # query_result | entity_snapshot | none
license:
  name: "NCCN proprietary"
  url: "https://www.nccn.org/permissions"
  spdx_id: null                     # SPDX якщо застосовно (e.g. "CC-BY-4.0", "CC0-1.0")
attribution:
  required: true
  text: "Reproduced with permission from the NCCN Clinical Practice Guidelines..."
  logo_url: null
commercial_use_allowed: false
redistribution_allowed: false
modifications_allowed: false
sharealike_required: false
known_restrictions:
  - "No redistribution of content; only our paraphrase + link per SOURCE_INGESTION_SPEC §1.2"
legal_review:
  status: "reviewed"                # pending | reviewed | escalated
  reviewer: null
  date: null
  notes: null

# Related
relates_to_diseases: [DIS-HCV-MZL, DIS-DLBCL, DIS-FOLLICULAR-LYMPHOMA, "..."]

notes: >
  Primary reference for all B-cell lymphoma indications. Updated
  quarterly. Check for new versions every 3 months as part of
  knowledge base hygiene (CCS §9.1).

last_verified: "2026-04-15"
verifier: [reviewer-id]
```

**Fields повторюються з SOURCE_INGESTION_SPEC §3.** Два документи
описують те ж саме; при розбіжності SOURCE_INGESTION_SPEC переможе
як пізніший і більш детальний спеціалізований документ.

---

## 15. Overall data model (relational view)

For developers, relational mapping:

```
DISEASE (1) ──────< (N) INDICATION >──────── (1) REGIMEN
                       │                         │
                       │                         ├──< (N) DRUG (via components)
                       │                         │
                       │                         ├── (1) MONITORING_SCHEDULE
                       │                         │
                       │                         └──< (N) SUPPORTIVE_CARE (mandatory)
                       │
                       ├──< (N) CONTRAINDICATION (hard)
                       │
                       ├──< (N) RED_FLAG (triggers alternative)
                       │
                       ├──< (N) TEST (required / desired)
                       │
                       └──< (N) SOURCE (evidence)

ALGORITHM (1) ──────< (N) INDICATION (outputs)
          └──────< (N) RED_FLAG (uses as inputs)

BIOMARKER ──── linked_via ──── INDICATION, DISEASE, DRUG
```

---

## 16. Storage options

Schema is **format-agnostic**. Three reasonable implementations:

### 16.1. YAML files in git (MVP recommended)

```
knowledge_base/
├── diseases/
│   └── hcv_mzl.yaml
├── drugs/
│   ├── rituximab.yaml
│   └── bendamustine.yaml
├── regimens/
│   ├── br.yaml
│   └── r_chop.yaml
├── indications/
│   ├── hcv_mzl_1l_standard.yaml
│   └── hcv_mzl_1l_aggressive.yaml
├── contraindications/
├── red_flags/
├── tests/
├── supportive_care/
├── monitoring/
├── algorithms/
└── sources/
```

**Переваги:**
- Git history = complete audit trail
- Standard OSS workflow (PRs, reviews)
- Клініцисти можуть редагувати у текстовому редакторі
- Human-readable, human-reviewable
- No database infrastructure needed for MVP

**Мінуси:**
- Referential integrity не enforced автоматично — потрібен валідатор
- Performance обмежена для великих KBs (тисячі entities)

### 16.2. PostgreSQL з JSON columns

Для версії, коли knowledge base виростає:
- Core fields — typed columns
- Flexible content (trees, conditions) — JSONB
- Referential integrity через foreign keys
- Повнотекстовий пошук built-in

### 16.3. Graph database (Neo4j, ArangoDB)

Оптимально для складних декілька-hop queries (biomarker → drugs → regimens → ...).
Overkill для MVP.

**Рекомендація:** почати з 16.1, перейти на 16.2 коли тестова нозологія
доведе life (шкалювання + production reliability).

---

## 17. Validation tooling

Що розробник має побудувати з першого дня:

**Entity validator:**
- Перевіряє, що всі required fields заповнені
- Перевіряє, що всі `_id` references валідні (не dangling)
- Перевіряє, що `version` semantic і увеличивается
- Перевіряє, що `last_reviewed` не старіше threshold

**Source checker:**
- Перевіряє, що всі sources існують у `sources/`
- Перевіряє, що URLs доступні (periodic check)
- Перевіряє `currency_status` не `superseded` без `superseded_by`

**Clinical review enforcer:**
- Перевіряє, що кожна Indication має >= 2 reviewers
- Перевіряє, що reviewers — з approved list
- Блокує merge без approval від required number

**CI/CD pipeline:**
```yaml
# .github/workflows/knowledge_validation.yml
on: pull_request
jobs:
  validate:
    steps:
      - validate_entity_schemas
      - check_referential_integrity
      - verify_source_availability
      - check_review_requirements
      - run_clinical_tests  # sample patient cohort
```

---

## 18. Governance цього документа

- Зміни в Schema потребують consensus всіх Clinical Co-Leads + Tech Lead
- 14 днів public comment перед major version
- Breaking changes (renaming fields, changing types) — major version bump
- Changelog в CHANGELOG-SCHEMA.md

---

## 19. Поточний статус і обмеження

**v0.1 означає:**
- Skeleton для першого enrolment — HCV-MZL
- Потребує refactoring після first real implementation
- Не валідований на інших нозологіях

**Відомі обмеження:**
- Не моделюються: clinical trial matching (потрібен окремий entity), genetic syndromes (як in germline BRCA), multidisciplinary coordination
- Fine-grained dose modifications — спрощено
- Temporal reasoning (що через скільки) — обмежений
- Interaction з patient preferences — ще не моделюється

**Що треба зробити після v0.1:**
- Реалізувати HCV-MZL в повному обсязі за цією schema
- Порівняти згенерований output з reference document
- Iterate на основі gaps

---

**Pull requests на Schema — welcomed, але через governance CHARTER §6.**


---

## 17. PROPOSAL — Solid-tumor extensions (2026-04-26)

**Status:** open. Drives 5 GI diagnoses (CRC, gastric/GEJ, PDAC, HCC,
esophageal). Each is committed initially as `partial` until the proposal
resolves.

**Why now:** OpenOnco v0.1 was built around hematolymphoid diseases where
1L = "pick a chemo regimen + monitoring". Solid tumors introduce three
patterns the schema does not represent today:

1. **Sequential phases inside one line of therapy.** Periop FLOT
   (gastric) = neoadjuvant chemo cycles 1–4 → surgery → adjuvant chemo
   cycles 5–8. CROSS (esophageal) = neoadjuvant CRT → esophagectomy →
   optional adjuvant ICI. Today `Indication.followed_by` means "next
   line", not "next phase of this 1L bundle"; engine and render layers
   don't model intra-line ordering.

2. **Surgery as a treatment modality.** Whipple (PDAC), low-anterior
   resection (rectum), gastrectomy (gastric), esophagectomy, hepatic
   resection / transplant (HCC) are first-line treatments. Today there
   is no Surgery entity. Treating surgery as a `Drug` is wrong; treating
   it as a free-text note loses the resectability gate, MDT-trigger, and
   complication linkage.

3. **Radiation therapy as concurrent / sequential treatment.** CROSS =
   41.4 Gy in 23 fractions concurrent with carbo-paclitaxel; rectal SCRT
   = 25 Gy / 5 fx; HCC SBRT; definitive CRT for esophageal squamous
   unresectable. RT dose / fractionation / target volume / OARs / total
   BED have no representation. Concurrent chemo-RT is doubly
   unmodellable today.

### 17.1. Proposed entities (sketch — to be ratified)

```yaml
# entity_type: Surgery
id: SUR-WHIPPLE
names: {preferred: "Pancreaticoduodenectomy (Whipple)"}
type: pancreaticoduodenectomy
intent: curative  # | palliative | diagnostic | salvage
target_organ: pancreas_head
applicable_diseases: [DIS-PDAC]
operative_mortality_pct: "1-3% in high-volume centers"
common_complications:
  - {name: "POPF (pancreatic fistula)", frequency: "10-20%"}
  - {name: "Delayed gastric emptying", frequency: "15-25%"}
sources: [SRC-NCCN-PANCREATIC-2025, SRC-ESMO-PANCREATIC-2024]

# entity_type: RadiationCourse
id: RT-CROSS-NEOADJ
names: {preferred: "CROSS neoadjuvant CRT"}
total_dose_gy: 41.4
fractions: 23
fraction_size_gy: 1.8
target_volume: "primary + involved nodes (CTV)"
schedule: "5 fx/week × 4.6 weeks"
concurrent_chemo_regimen: REG-CARBOPLATIN-PACLITAXEL-WEEKLY  # optional ID
intent: neoadjuvant  # | definitive | adjuvant | palliative
sources: [SRC-CROSS-2012, SRC-NCCN-ESOPHAGEAL-2025]

# Indication addition (extends §7 schema)
applicable_to:
  ...existing fields...
phases:                       # NEW — ordered list within ONE indication
  - phase: neoadjuvant
    type: chemotherapy        # | surgery | radiation | chemoradiation
    regimen_id: REG-FLOT
    cycles: 4
  - phase: surgery
    type: surgery
    surgery_id: SUR-TOTAL-GASTRECTOMY
  - phase: adjuvant
    type: chemotherapy
    regimen_id: REG-FLOT
    cycles: 4
```

### 17.2. Engine + render impact

- `engine.algorithm_eval` already returns one Indication per
  algorithm; with `phases:` populated, render layer must walk the
  ordered list and emit a phased timeline (current `_render_timeline`
  composes induction → response → maintenance from regimen + monitoring;
  `phases:` is an explicit override).
- Surgery and RadiationCourse become first-class entity types in
  `validation/loader.py`. New referential-integrity checks: every
  `phases[*].surgery_id` resolves to a Surgery; every `radiation_id`
  resolves to a RadiationCourse.
- Fixture-level testing: golden fixtures exercise the phased-output
  contract per disease.

### 17.3. Interim handling (the diseases shipped in this commit)

Until the proposal is ratified by clinical co-leads and engine work
lands:

- All 5 GI diseases are committed with `archetype: stage_driven` (HCC
  also keeps `etiological_factors` populated — see §3.3 — but its
  primary archetype is `stage_driven` via BCLC).
- Indications use only the existing `applicable_to.stage_requirements`
  + `recommended_regimen` + `concurrent_therapy` + `followed_by` slots.
  Where periop sequencing is clinically essential (FLOT, CROSS, mFOLFIRINOX
  adjuvant), the regimen entry is the "main pharma cycle" and the
  surgical / RT step is described in `Indication.notes` as free text.
  This is **lossy** — the engine cannot enforce "did surgery happen
  before adjuvant?" — and is the explicit reason the diseases are marked
  `partial`.
- Each affected disease YAML carries:
  ```yaml
  metadata:
    proposal_status: partial
    awaiting_proposal: "KNOWLEDGE_SCHEMA_SPECIFICATION.md §17 Solid-tumor extensions"
  ```

### 17.4. Resolution path

1. Clinical co-leads review §17.1 and either ratify or counter-propose.
2. Pydantic schemas added: `surgery.py`, `radiation_course.py`,
   `Indication.phases: list[IndicationPhase]`.
3. Loader-side referential integrity for surgery/RT IDs.
4. Engine: pass-through of `phases` into `PlanTrack.indication_data`.
5. Render: phased-timeline section.
6. Tests: golden fixtures per disease that assert the phased output.
7. Re-stamp affected diseases as `proposal_status: full` and remove the
   `awaiting_proposal` field.
